Effect of gene environment interactions on lung function and cardiovascular disease in COPD by Hackett, Tillie-Louise et al.
© 2011 Hackett et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2011:6 277–287
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
277
OrIgInAL reseArCH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/COPD.s18279
effect of gene environment interactions on lung 
function and cardiovascular disease in COPD
Tillie-Louise Hackett1,2,*
Dorota stefanowicz1,*
Farzian Aminuddin1
Don D sin1
John e Connett3
nicholas r Anthonisen4
Peter D Paré1
Andrew J sandford1
1University of British Columbia, James 
Hogg research Laboratories, st Paul’s 
Hospital, Division of respirology, 
Department of Medicine, 2Department 
of Anesthesiology, Pharmacology, and 
Therapeutics, University of British 
Columbia, Vancouver, BC, Canada; 
3school of Public Health, University 
of Minnesota, Minneapolis, Mn, UsA; 
4Faculty of Medicine, University of 
Manitoba, Winnipeg, MB, Canada
*These authors contributed equally to 
this work
Correspondence: Andrew sandford 
UBC James Hogg research Centre  
at the Heart and Lung Institute,  
st Paul’s Hospital, 1081 Burrard street, 
Vancouver, BC, Canada V6Z 1Y6 
Tel +1 604 806 8346 
Fax +1 604 806 8351 
email andrew.sandford@hli.ubc.ca
Background: The objective of this study was to determine if gene-environment interactions 
between cigarette smoking and interleukin-6 (IL6), interferon-γ (IFNG), interleukin-1β (IL1B), 
or interleukin-1 receptor antagonist (IL1RN) single nucleotide polymorphisms are associ-
ated with lung function decline and cardiovascular disease in chronic obstructive pulmonary 
disease (COPD).
Methods: Single nucleotide polymorphisms (SNPs) in IL6, IFNG, IL1B, and IL1RN were 
genotyped in the Lung Health Study and correlated with rate of decline of forced expiratory 
volume in 1 second (FEV1) over 5 years, baseline FEV1, serum protein levels, cardiovascular 
disease, and interactions with smoking.
Results: The IL6 rs2069825 single nucleotide polymorphism was associated with the rate of 
decline of prebronchodilator FEV1 (P = 0.049), and was found to have a significant interac-
tion (P = 0.004) with mean number of cigarettes smoked per day. There was also a significant 
interaction of IFNG rs2069727 with smoking on prebronchodilator (P = 0.008) and postbron-
chodilator (P = 0.01) FEV1. The IL6 polymorphism was also associated with cardiovascular 
disease in heterozygous individuals (P = 0.044), and was found to have a significant interaction 
with smoking (P = 0.024). None of the genetic variants were associated with their respective 
serum protein levels.
Conclusion: The results suggest interactions of IL6 rs2069825 and IFNG rs2069727 single 
nucleotide polymorphisms with cigarette smoking on measures of lung function. The IL6 
rs2069825 single nucleotide polymorphism also interacted with smoking to affect the risk of 
cardiovascular disease in COPD patients.
Keywords: gene-environment interactions, interleukin-6, forced expiratory volume in one 
second, cardiovascular disease, chronic obstructive pulmonary disease
Introduction
Cigarette smoking is responsible for nearly five million deaths annually, with the leading 
cause of tobacco-related mortality being cardiovascular disease, followed by chronic 
obstructive pulmonary disease (COPD).1 While the adverse effects of cigarette smoking 
on lung health and “systemic” diseases are well established, the precise mechanism 
by which cigarette smoke mediates its systemic effects needs to be clarified. Due to 
the large variation in the adverse effects of cigarette smoke, it has been proposed that 
other factors, such as gene-environment interactions, may be important in promoting 
tobacco-related disease.2,3 COPD represents a clear example of gene-environment 
interactions because although cigarette smoking is the main environmental trigger 
for COPD in developed countries, considerable variation exists in disease outcomes, 
which are likely related to an individual’s genetic load. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Pulmonary inflammation is central to the development of 
COPD, characterized by increased numbers of neutrophils, 
macrophages, and lymphocytes, leading to the destruction 
of lung parenchyma, goblet cell hypertrophy, and tissue 
remodeling. In some patients, COPD is associated with 
systemic effects, which include cachexia, skeletal muscle 
wasting, and increased comorbidities, such as cardiovascular 
disease.4 These systemic effects may be caused or sustained 
by the enhanced systemic inflammation observed in some 
COPD patients.
Due to the complexity of the inflammatory mediators 
released by immune cells in response to smoking, mul-
tiple mediators have been suggested to be involved in the 
progression of COPD. We have previously demonstrated 
the association between interleukin-6 (IL6), interferon-γ 
(IFNG), interleukin-1β (IL1B), and interleukin-1 receptor 
antagonist (IL1RN) polymorphisms and a rapid decline or 
baseline level of lung function in smokers.5–7 The Lung 
Health Study (LHS) is a multicenter community-based 
cohort of smokers with mild to moderate airflow limitation.8 
Our previous studies utilized a subset of individuals from 
the LHS cohort to form a nested case-control study based 
on the extremes of distribution for the rate of decline in 
lung function and baseline lung function.5–7 Our rationale in 
this study was to investigate if gene × smoking interactions 
were associated with lung function decline in the entire LHS 
cohort. This approach would therefore allow us to estimate 
the effect of the identified polymorphisms and interactions 
with smoking on continuous measures of lung function, 
rather than dichotomous extremes, which the previous 
subset analyses were underpowered to perform. Our second 
aim was to determine whether the genetic variants and/or 
gene ×   smoking interactions were predictors of cardiovas-
cular disease. We hypothesized that the link between COPD 
and mortality from cardiovascular disease is inflammation, 
through both local and systemic mechanisms.
Methods
LHs participants
The details of the LHS cohort have previously been pub-
lished.8 Briefly, 5887 subjects who were cigarette smokers, 
aged 35–60 years, with mild to moderate airflow obstruction 
were recruited into the LHS cohort. Airflow obstruction 
was defined by a forced expiratory volume in one second 
(FEV1) to forced vital capacity (FVC) ratio of #0.70 and 
FEV1 55%–90% of predicted. Lung function measurements 
were performed annually over the 5 years of the study using 
standardized spirometry, with quality control in accordance 
with the American Thoracic Society guidelines.9,10 Dur-
ing the follow-up phase of the study, the vital status of the 
participants was captured every 6 months. An independent 
mortality and morbidity committee reviewed death certifi-
cates, autopsy reports, and relevant hospital records to assign 
the causes of death for all participants who died during the 
study and confirmed data by linkage with the US National 
Death Index.11
On recruitment into the LHS cohort, each individual’s 
smoking history was recorded in pack-years. At each sub-
sequent annual visit, the smoking status of each participant 
was ascertained based on self-reporting and was objectively 
verified by determining cotinine levels in saliva samples and/
or carbon monoxide concentrations in expired air (Minico, 
Catalyst Research or EC50, Vitalograph). Participants were 
categorized as continued smokers or sustained quitters based 
on self-reporting and a validated biochemical measurement 
at all five follow-up visits.8
Individuals who had a history of cancer (except carci-
noma in situ or basal cell carcinoma of the skin), myocardial 
infarction (in the past 2 years), angina, heart failure, stroke 
(in the past 2 years), renal failure, insulin-requiring diabetes 
mellitus, cirrhosis or other serious liver disease, pulmonary 
embolism, disorders of the central nervous system, narrow-
angle glaucoma, or any other major diseases which could have 
compromised follow-up, were excluded from the cohort.
Polymorphism selection  
and genotyping methods
Four single nucleotide polymorphisms (SNPs) were selected 
because they showed significant associations with either rate 
of decline or baseline lung function in our previous nested 
case-control studies of the LHS cohort.5–7 In addition, the 
respective proteins have previously been implicated in the 
pathogenesis of cardiovascular disease.12–17 Genotyping was 
performed using the TaqMan method (Applied Biosystems, 
Foster City, CA).
serum IL6, IL1β, IL1RN, and IFNG 
concentrations
At the fifth annual visit, DNA and serum was isolated using 
venipuncture. The serum samples were stored at -70°C and 
used to measure the concentrations of IL6, IL1β, IL1RN, and 
IFNG using a highly sensitive chemiluminescent multiplexed 
sandwich immunoassay (SearchLight Proteome Array 
System, Rockford, IL).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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statistical analysis
Hardy–Weinberg equilibrium was assessed using χ2 
  goodness-of-fit tests, and linkage disequilibrium estimations 
were performed using the CubeX cubic exact solutions 
  program.18 Multivariate linear regressions for prebronchodila-
tor and postbronchodilator rate of decline were performed to 
test for associations with each SNP. The confounding factors 
included for these analyses were age, body mass index, smoking 
status (continuous   versus noncontinuous), and mean number of 
cigarettes smoked per day during the LHS follow-up period.
Multivariate linear regressions for baseline FEV1% pre-
dicted were performed to test for associations with each SNP. 
Confounding factors included for analyses of baseline lung 
function were age, body mass index, and pack-years of smok-
ing. Pack-years of smoking was used as the covariate because 
this smoking measure was thought to be the most representative 
of patient smoking history prior to the start of the study.
Multivariate logistic regressions were used to test for the 
association of each SNP with cardiovascular disease and fatal 
cardiovascular disease.
Multivariate linear regressions were also performed to test 
for association of each SNP with logarithmically transformed 
serum levels of their respective proteins, with age, body mass 
index, and pack-years of smoking included as covariates.
Rate of decline in lung function was determined by the 
difference between lung function at the start and end of 
the study divided by the number of years between the two 
measurements. Gene × smoking interactions were tested in 
the entire LHS cohort by adding a multiplicative term to the 
regression models.
The single locus analyses described above were per-
formed using the JMP statistical package (SAS Institute Inc, 
Cary, NC). Haplotype analysis was done using the SimHap 
package.19 If we were to apply a Bonferroni correction for the 
total number of 29 comparisons conducted in this study, there 
would be no association that would survive this stringent 
level of correction. Because many of the phenotypes and 
the IL1B and IL1RN SNPs tested were significantly associ-
ated, we used a matrix spectral decomposition approach to 
estimate the effective number of independent phenotypes 
and genotypes.20 Using the matrix spectral decomposition 
approach, the total effective number of variables (Veff) tested 
for IL6, IFNG, IL1B, and IL1RN was 8.15, 7.25, 9, and 9, 
respectively. The significance threshold required to keep the 
Type I error rate at 5% (0.05/Veff) for IL6, IFNG, IL1B, and 
IL1RN was 6.137 × 10-3, 6.894 × 10-3, 5.555 × 10-3, and 
5.555 × 10-3, respectively, for each gene.
Results
Characteristics of study participants
Of the 5887 LHS participants, 4189 had DNA and com-
plete phenotypic data available. Of those, 4036 (96%) were 
of European descent and were utilized in the subsequent 
analyses because we had insufficient power to study the 
other ethnic groups. The total cohort (n = 4036) was used to 
investigate gene × smoking interactions on lung function, the 
effects of polymorphisms on serum levels of their respective 
proteins, and the influence of genetic variants on cardiovas-
cular disease. The subset of LHS participants (n = 2523) that 
had not been previously included in genetic studies of these 
polymorphisms was used to investigate associations with 
lung function measures. The demographic characteristics of 
the LHS participants are shown in Table 1.
Table  1  Distribution  of  demographic  characteristics  for 
participants in the Lung Health study
Total cohort Subseta
(N = 4036) (N = 2523)
gender (F/M) 1479/2557 925/1598
Age (years) 48.51 (6.74) 48.54 (6.69)
smoking history (pack yearsb) 40.26 (18.29) 40.36 (18.12)
Mean cigarettes/dayc 15.09 (13.55) 13.97 (13.69)
smoking status during 5-year follow-upd
  Continuing smokers 2177 1169
  Intermittent quitters 1148 833
  sustained quitters 711 521
BMI (kg/m2) 25.52 (3.83) 25.56 (3.84)
Baseline FeV1 (% predicted pre-BD)e 75.41 (8.87) 76.18 (6.57)
Baseline FeV1 (% predicted post-BD)f 78.55 (9.20) 79.16 (5.88)
∆ FEV1/year (% predicted pre-BD)g -0.83 (1.67) -0.72 (1.37)
∆ FEV1/year (% predicted post-BD)h -0.64 (1.57) -0.51 (1.36)
Median (IQr) IL6 (pg/mL) 2.6 (1.8–4.3) nA
Median (IQr) IFnγ (pg/mL) 6.1 (3.4–14.2) nA
Median (IQr) IL1rn (pg/mL) 138 (96–198) nA
Median (IQr) IL1β (pg/mL) 1.27 (0.79–2.44) nA
Cardiovascular disease death (yes/no) 71/3965 nA
Cardiovascular disease (yes/no) 705/3331 nA
Notes: aexcluding participants in previous studies; bnumber of packs of cigarettes 
smoked per day times number of years smoking;  cnumber of cigarettes smoked 
per day during 5-year follow-up; dContinuing smokers: participants who reported 
smoking at each annual visit. sustained quitters: participants who were validated 
by  salivary  cotinine  or  exhaled  carbon  monoxide  levels  as  abstinent  at  every 
annual visit. Intermittent quitters: participants who were not sustained quitters or 
continuing smokers;  eLung function at the start of the LHs measured as FeV1 % 
predicted pre-bronchodilator; fLung function at the start of the LHs measured as 
FeV1 % predicted post-bronchodilator;  gChange in lung function per year over a 
5-year period as % predicted FeV1 pre-bronchodilator;  hChange in lung function 
per year over a 5-year period as % predicted FeV1 post-bronchodilator. Values are 
means ± sD for continuous data unless otherwise stated.
Abbreviations: BD, bronchodilator; BMI, body mass index; FeV1, forced expiratory 
volume in 1 second; IL6, interleukin-6; IFnγ, interferon gamma; IL1rn, interleukin 1 
receptor antagonist; IL1β, interleukin-1β; IQr, interquartile range. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Frequency of snP alleles and genotypes in the total cohort (n = 4036)
Gene SNP Allelesa Chromosomal locationb Position in gene Minor allele 
frequency (%)
Genotype 
frequency (%)
AA AB BB
IL6 rs2069825 CT/- 7: 22765341–22765342 Promoter 39 38 46 16
IFng rs2069727 A/g 12: 68548223 3′ region 47 29 49 22
IL1rn rs419598 T/C 2: 113887207 exon 3 27 53 39 8
IL1B rs16944 C/T 2: 113594867 Promoter 33 45 44 11
Notes: aThe first allele is the major allele, the second is the minor allele; bChromosome: base position (nCBI Build 37.1).
Polymorphism genotyping assays, linkage 
disequilibrium, and Hardy–Weinberg 
equilibrium
In our previous study of IL1B and IL1RN polymorphisms, 
we genotyped a variable number of tandem repeats in intron 
2 of the IL1RN gene.7 In order to facilitate rapid genotyping 
of the large number of samples in this study, we utilized 
a SNP (rs419598) that was reported to be in high linkage 
disequilibrium with the tandem repeat polymorphism.21 
We confirmed this association in a sample of 571 LHS 
participants for whom we had genotypic information for 
both polymorphisms. The linkage disequilibrium statistic 
between the tandem repeat (considering alleles A1 and A2) 
and rs419598 in these individuals was r2 = 0.97.
We genotyped the LHS participants for four poly-
morphisms, ie, rs2069825 in IL6, rs2069727 in IFNG, 
rs16944 in IL1B, and rs419598 in IL1RN. In the total 
of 4032 individuals, genotyping success rates were in 
the range of 91.8%–96.2%. The frequencies of the SNP 
alleles and genotypes are listed in Table 2. All SNPs were 
in Hardy  –Weinberg equilibrium in all groups, except for 
IL6 rs2069825, for which there was a slight excess of 
heterozygotes (P = 0.02).
Analysis of rate of decline and baseline FeV1
We analyzed each polymorphism for association with rate of 
decline of prebronchodilator and postbronchodilator FEV1 
in the LHS participants not previously studied for these vari-
ants. In contrast with our previous studies,5,6 there was no 
association of any polymorphism with the rate of decline of 
lung function (Table 3). Similarly, there was no association 
of the polymorphisms with measures of baseline lung func-
tion in the same subset of individuals (Table 3). However, 
when we analyzed the entire LHS cohort (P = 0.0486) and 
the original subset of patients (P = 0.0063) we did find a 
significant effect of the IL6 rs2069825 SNP on the rate of 
decline of prebronchodilator FEV1 (Table 4).
We had previously found a significant association of 
IL1B and IL1RN haplotypes with rate of decline of lung 
function.7 Therefore, we tested haplotypes of the rs16944 
and rs419598 polymorphisms in the LHS cohort not previ-
ously tested. Contrary to our previous results, none of the 
haplotypes were associated with the rate of decline of lung 
function or with baseline lung function. When we analyzed 
the entire LHS cohort, we also found no significant asso-
ciations except with the original subset analysis (data not 
shown).
Analysis of gene × smoking interactions
We investigated gene × smoking interactions in the entire 
LHS cohort. The data in Table 4 suggested a recessive 
effect of the IL6 rs2069825 SNP and therefore interac-
tions of this polymorphism were explored in a recessive 
model. We found a significant interaction (P = 0.0044) of 
the IL6 rs2069825 SNP with mean number of cigarettes 
smoked per day on rate of decline of prebronchodilator 
FEV1 (Table 5) which remained significant after correc-
tions for multiple comparisons by gene (P = 0.0359). This 
interaction is illustrated in Figure 1, which shows a faster 
rate of decline in individuals with the IL6 rs2069825 [–/–] 
genotype. There was also a significant overall interaction 
of IFNG rs2069727 with smoking on prebronchodilator 
(P = 0.0098) and postbronchodilator (P = 0.0077) FEV1 
(Table 5). There were no significant gene × smoking 
interactions on lung function parameters with the other 
polymorphisms studied.
Analysis of serum protein levels
We determined whether each of the four polymorphisms 
was associated with the serum level of its respective 
protein. However, none of the genetic variants was 
significantly associated with the protein levels of IL6, 
IL1β, IL1RN, or IFNγ measured in peripheral blood   
(P = 0.176–0.599).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Analysis of rate of decline and baseline of FeV1 in the LHs subset not previously studied
Gene Polymorphism Genotypea β (% predicted/year) SE P value
Rate of decline of pre-bronchodilator FEV1
IL6 rs2069825 CT/CT – – –
-/CT -0.0404 0.0369 0.2733
-/- 0.0378 0.0475 0.4267
IFNG rs2069727 A/A – – –
A/g 0.0178 0.0354 0.6142
g/g -0.0078 0.0425 0.8540
IL1RN rs419598 T/T – – –
C/T 0.0351 0.0438 0.4228
C/C -0.0462 0.0644 0.4728
IL1B rs16944 C/C – – –
C/T 0.0333 0.0387 0.3897
T/T -0.0477 0.0535 0.3729
Rate of decline of post-bronchodilator FEV1
IL6 rs2069825 CT/CT – – –
-/CT -0.0632 0.0358 0.0776
-/- 0.0218 0.0462 0.6366
IFNG rs2069727 A/A – – –
A/g 0.0150 0.0343 0.6605
g/g -0.0198 0.0412 0.6306
IL1RN rs419598 T/T – – –
C/T -0.0239 0.0425 0.5736
C/C 0.0095 0.0626 0.8787
IL1B rs16944 C/C – – –
C/T 0.0394 0.0377 0.2951
T/T -0.0408 0.0520 0.4321
Baseline level of pre-bronchodilator FEV1
IL6 rs2069825 CT/CT – – –
-/CT -0.0300 0.1853 0.8712
-/- -0.2074 0.2390 0.3856
IFNG rs2069727 A/A – – –
A/g -0.1192 0.1794 0.5064
g/g 0.2640 0.2154 0.2205
IL1RN rs419598 T/T – – –
C/T -0.3209 0.2217 0.1478
C/C 0.3707 0.3264 0.2562
IL1B rs16944 C/C – – –
C/T -0.1483 0.1958 0.4487
T/T 0.0501 0.2702 0.8528
Baseline level of post-bronchodilator FEV1
IL6 rs2069825 CT/CT – – –
-/CT -0.0262 0.1659 0.8747
-/- -0.2546 0.2139 0.2342
IFNG rs2069727 A/A – – –
A/g -0.1650 0.1606 0.3043
g/g 0.3989 0.1928 0.0386
IL1RN rs419598 T/T – – –
C/T -0.2209 0.1980 0.2649
C/C 0.1958 0.2917 0.5021
IL1B rs16944 C/C – – –
C/T -0.2444 0.1749 0.1625
T/T 0.0098 0.2415 0.9677
Notes: aThe first allele is the major allele, the second is the minor allele. 
Abbreviations: FeV1, forced expiratory volume in 1 second; IFnγ, interferon gamma; IL1rn, interleukin 1 receptor antagonist; IL6, interleukin-6; IL1β, interleukin-1β.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Analysis of cardiovascular disease  
and fatal cardiovascular disease
There was an association of the IL6 polymorphism with 
cardiovascular disease, although there was only an effect 
of the heterozygous genotype (P = 0.0446). There was no 
association of the IFNG polymorphism or IL1B-IL1RN 
haplotypes with either cardiovascular disease outcome. In 
addition, we found a significant gene × smoking interaction 
between cardiovascular disease and the IL6 polymorphism 
(P = 0.0239, Table 6).
Discussion
We have investigated polymorphisms in the IL6, IL1RN, IL1B, 
and IFNG genes which have previously been demonstrated 
as risk factors for accelerated decline in lung function or 
baseline lung function in COPD patients. Unlike our previous 
studies, which used nested case-control designs including 
patients within the extremes of distribution for lung func-
tion parameters, we only found an association for IL6 with 
rate of decline in lung function for the entire LHS cohort. 
We found significant gene × smoking interactions between 
IL6 and IFNG and the rate of decline in lung   function and 
  baseline FEV1, respectively. In addition, we also demonstrated 
a significant association between IL6 and an IL6 × smoking 
interaction for cardiovascular disease.
The current paradigm for the pathogenesis of COPD 
includes a local and systemic inflammatory response to 
environmental challenges, notably cigarette smoking, which 
ultimately results in airflow obstruction. In COPD patients, 
high levels of serum or sputum IL6 have been associated 
with impaired lung function, exacerbations, pulmonary 
infections, and skeletal muscle weakness.22–27 It has also been 
Table 4 Analysis of rate of decline of FeV1 in the entire LHs cohort
Gene Polymorphism Genotypea β (% predicted/year) SE P value
Rate of decline of pre-bronchodilator FEV1
IL6 rs2069825 CT/CT – – –
-/CT 0.0582 0.0356 0.1020
-/- -0.1130 0.0460 0.0141
Notes: aThe first allele is the major allele, the second is the minor allele.
Abbreviation: FeV1, forced expiratory volume in 1 second; IL6, interleukin-6.
Table 5 Analysis of gene × smoking interactions on lung function
Term β SE P value
Rate of decline of pre-bronchodilator FEV1
Age -0.0354 0.0038 ,0.0001
BMI 0.0207 0.0066 0.0018
smoking status [Continuous]a -0.2521 0.0340 ,0.0001
Mean cigarettes per dayb -0.0274 0.0030 ,0.0001
IL6 rs2069825 [–/–] -0.0851 0.0344 0.0136
IL6 rs2069825 [–/–] × Mean cigarettes per day -0.0071 0.0025 0.0044
Baseline level of pre-bronchodilator FEV1
Age -0.1346 0.0229 ,0.0001
BMI -0.0926 0.0371 0.0125
smoking history (pack-years) -0.0354 0.0088 ,0.0001
IFNG rs2069727 [A/g] 0.2841 0.1891 0.1331
IFNG rs2069727 [g/g] -0.3918 0.2280 0.0858
IFNG rs2069727 [A/g] × smoking history -0.0316 0.0126 0.0023
IFNG rs2069727 [g/g] × smoking history 0.0207 0.0158 0.0996
Baseline level of post-bronchodilator FEV1
Age -0.2151 0.0236 ,0.0001
BMI -0.0142 0.0382 0.7102
smoking history (pack-years) -0.0445 0.0091 ,0.0001
IFNG rs2069727 [A/g] 0.3225 0.1947 0.0977
IFNG rs2069727 [g/g] -0.4193 0.2347 0.0742
IFNG rs2069727 [A/g] × smoking history -0.0326 0.0107 0.0023
IFNG rs2069727 [g/g] × smoking history 0.0279 0.0129 0.0310
Notes: anumber of packs of cigarettes smoked per day times number of years smoking; bnumber of cigarettes smoked per day during 5-year follow-up.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; IL6, interleukin-6; IFnγ, interferon gamma.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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demonstrated that overexpression of IL6 in the adult murine 
lung results in airway inflammation and emphysema-like 
airspace enlargement.28 In this study, we found the IL6 SNP 
rs2069825 deletion allele was associated with rate of decline 
of prebronchodilator FEV1 in the entire LHS cohort. In a pre-
vious independent case-control sample study, associations 
of IL6 SNPs with COPD susceptibility were also found. In 
particular, these IL6 SNP were in high linkage disequilib-
rium with the IL6 SNP rs2069825 genotyped in the present 
study.5 IL6 haplotypes, including rs2069825, have been 
previously associated with COPD in an independent study 
of a Caucasian population.29 Furthermore, IL6 haplotypes 
have been found to be associated with COPD defined by 
lung function in a Spanish population.30 In contrast, a much 
smaller study has previously reported no association of an 
IL6 SNP (rs1800795) with COPD.31 The rs1800795 polymor-
phism is in high linkage disequilibrium (r2 = 0.9) with the 
IL6 rs2069825 SNP investigated in this study. Because we 
believe that the associations found in well-powered cohorts 
are not likely to represent false   positive results, together these 
studies indicate an association of IL6 SNPs with COPD. In 
contrast with our previous study in which we analyzed the 
association of the IL6 rs2069825 SNP with individuals not 
defined within the extremes of decline of lung function, we 
found no significant effect. However, when we analyzed the 
entire LHS cohort and the original subset of patients for 
rate of decline in prebronchodilator FEV1, we did confirm 
the findings of our previous study.5 Our finding of an IL6 
rs2069825 interaction with level of smoking indicates that 
other factors are required for the effect of IL6 rs2069825 
to manifest. Indeed, this is the first study to demonstrate 
a gene × environment interaction for IL6 and smoking with 
a lung function parameter.
The number of IFNγ-expressing lymphocytes is elevated 
in smokers and COPD bronchial biopsies.32 Studies of IFNγ 
knockout mice have also demonstrated an important role 
for IFNγ in emphysema.33 The IFNG rs2069727 SNP was 
previously associated with baseline lung function in the LHS 
subset using the extremes of the distribution of lung func-
tion measurements.6 We also found a significant interaction 
with smoking history in our previous study.6 Therefore, the 
interaction of rs2069727 with pack-years of smoking in the 
total LHS cohort found in this study is consistent with these 
data. In support of the importance of IFNG, a different IFNG 
polymorphism (rs2430561) was previously associated with 
COPD in a Macedonian population.34 For the IL1RN rs419598 
and IL1B rs16944 polymorphisms, we found no associations 
with rate of decline or baseline FEV1. We could confirm our 
findings of the previous association study for IL1RN and 
IL1B in the subset, but not the whole LHS cohort. This sug-
gests that either the polymorphisms are only risk factors in 
the most severely affected individuals (those with very rapid 
decline in lung function), or the previous associations were 
false positive results.
It has long been recognized that smokers with COPD 
have high cardiovascular-related mortality.35,36 Indeed, 
decreased expiratory flow from the lung, which is the 
defining feature of COPD, increases the risk of isch-
emic heart disease, strokes, and sudden cardiac death by 
2–3-fold, independent of other risk factors.37 In particular, 
this increased risk is thought to be especially relevant to 
patients with mild to moderate COPD, because in severe 
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Figure 1 IL6 rs2069825 [-/-] genotype and rate of decline in lung function. Individuals 
in the Lung Health study cohort were genotyped for the IL6 rs2069825 single nucleotide 
polymorphism. Their genotype was plotted against mean cigarettes per day (x axis) 
and rate of decline (prebronchodilator FeV1 [y axis]). The slopes demonstrate a faster 
decline in individuals with a [-/-] genotype (triangles) compared with individuals with 
the heterozygote [-/C] or homozygote [C/C] genotypes (squares).
Table 6 Analysis of gene × smoking interactions on cardiovascular 
disease
Term β SE P value
gender [Male] -0.3537 0.0524 ,0.0001
Age -0.0762 0.0074 ,0.0001
BMI -0.0330 0.0122 0.0069
Mean cigarettes per daya -0.0001 0.0036 0.9664
Diastolic blood pressure at year 5 0.0261 0.0065 ,0.0001
systolic blood pressure at year 5 -0.0261 0.0039 ,0.0001
IL6 rs2069825 [-/CT] 0.1253 0.0624 0.0446
IL6 rs2069825 [-/-] -0.0475 0.0792 0.5489
IL6 rs2069825 [-/CT] × mean  
cigarettes per day
-0.0101 0.0045 0.0239
IL6 rs2069825 [-/-] × mean 
cigarettes per day
0.0010 0.0058 0.0873
Notes: anumber of cigarettes smoked per day during 5-year follow-up.
Abbreviations: BMI, body mass index; IL6, interleukin-6.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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COPD patients the primary cause of death is usually 
respiratory disease.11 The mechanisms of cardiovascular 
disease in COPD include hypoxia, systemic inflamma-
tion, and oxidative stress.38 Due to the poor correlations 
of circulating levels of   cytokines such as tumor necrosis 
factor and interleukin-8 with sputum levels in COPD, 
the data suggest that systemic inflammation may not be 
a simple spillover effect from lung   inflammation.39 Thus, 
intermediate factors may play an important role because 
smoking is associated with increased systemic levels of 
inflammatory mediators, including IL6, tumor necrosis 
factor, reactive oxygen species, and IFNγ.40,41 Although it 
is widely accepted that cigarette smoking induces systemic 
inflammation, which contributes to both the pathogen-
esis of COPD and cardiovascular disease morbidity and 
mortality,32,42 it is not known which inflammatory genes 
are important.
We found that the IL6 rs2069825 SNP was associated 
with cardiovascular   disease. The minor allele of the IL6 
promoter SNP, rs1800795 (-174G/C), has been previously 
  associated with increased circulating IL6 levels, cardiovas-
cular disease, and cardiovascular disease-related mortality 
in populations of older adults.43–46 However, IL6 gene varia-
tion was only weakly associated with serum IL6 levels and 
not with cardiovascular outcomes in the Cardiovascular 
Health Study.47 More recently, Carty et al studied several IL6 
SNPs in the Cardiovascular Health Study, including the IL6 
polymorphism, rs1554606,48 which is in moderate linkage 
disequilibrium (r2 = 0.49) with IL6 rs2069825, the SNPs 
used in our study. However, the study found no associations 
between the five IL6 SNPs investigated and cardiovascular 
outcomes.48 The differences in the findings for IL6 rs2069825 
and cardiovascular disease outcome potentially reflects the 
cohorts studied. The Cardiovascular Health Study consisted 
of older patients (mean 72.6 years), of whom 59.5% were 
female and only 11.0% were current smokers49 in comparison 
with our cohort, which consisted of only current smokers (on 
enrollment) with COPD that were 36.6% female and younger 
(mean 48.51 years).
The systemic inflammatory response is characterized 
by stimulation of the hematopoietic system. Circulating 
cytokines, such as IL6, have been postulated to stimulate 
the bone marrow to release leukocytes and platelets involved 
in systemic inflammation.50 Several studies have shown 
increased levels of systemic IL6 in smokers compared with 
never-smokers.51,52 Furthermore, IL6 has been found to corre-
late significantly with fibrinogen and white blood cell counts, 
reflecting a major role for IL6 as an inducer of fibrinogen,53 
which has been demonstrated to be an important marker in 
cardiovascular disease.54 In addition, levels of IL6 can be used 
to predict future cardiovascular disease.17,55 Indeed, in COPD, 
IL6 levels are increased, particularly during exacerbations, 
and IL6 levels parallel C-reactive protein levels.56
Our previous search for COPD susceptibility genes 
had focused on genes involved in the inflammatory 
response, but we had no intermediate phenotypes to test 
whether the significant associations we observed were 
acting through inflammatory pathways. The recent analy-
sis of serum samples from the LHS participants offered 
the opportunity to use measurements of serum proteins 
and cytokines as powerful intermediate phenotypes. We 
examined the association of our identified SNPs with IL6, 
IFNγ, IL1β, and IL1RN serum levels. We did not find any 
associations, and therefore we found no evidence that the 
associations we reported were mediated through an influ-
ence on the production of the serum cytokines measured. 
However, we did not measure cytokine levels within the 
lung, and therefore we could not test if the associations 
of IL6 rs2069825 with lung function are driven via local 
pulmonary expression.
There are several explanations for the lack of association 
between the SNPs studied and serum cytokine levels measured. 
Many serum proteins have been demonstrated to have marked 
diurnal variability, and the serum samples were not obtained at 
a specific time of day for all patients. Additionally, the serum 
half-life of cytokines such as IL6 is short. Another limitation 
is the lack of healthy nonsmoking control subjects, thus the 
relationship of these candidate genes to normal lung function 
decline with age and cardiovascular disease in a nonsmoking 
population is unknown.
Compared with previous studies, the strengths of this 
study include a larger sample size and good power. This 
sample size provides more than adequate power to detect 
common genetic risk variants, as shown in our previous 
power analyses.57 There were several potential limitations 
to the study. First, false positive results could have been 
generated by population stratification. However, previous 
studies have suggested that US Caucasian populations are 
unlikely to contain sufficient stratification to cause wide-
spread false positive results.58 One important difference 
with our previously identified associations between IL6, 
IFNγ, IL1β, and IL1RN polymorphisms and rate of decline 
and baseline lung function is that these studies utilized a 
case-control analysis that compared individuals from the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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extremes of the distribution for rate of decline or baseline 
lung function. When we analyzed the entire LHS cohort, 
only the IL6 rs2069825 SNP remained significant. This 
could indicate that the IFNG rs2069727, IL1RN rs419598, 
and IL1B   rs16944 polymorphisms previously identified are 
important only in individuals with severe airflow limita-
tion and rapid decline in lung function over the course of 
their disease. There may also be increased power to detect 
genetic susceptibility loci using extremes of the distribution 
of a continuous variable.59 However, it is also possible that 
previous studies were underpowered and the results obtained 
were false positives.
In this study, we have made multiple comparisons and 
therefore most of the results would not be significant at the 
5% level if a Bonferroni correction was made. On the other 
hand, only a limited number of SNPs were chosen based on 
a prior association with lung function measures in the LHS. 
Furthermore, the prebronchodilator and postbronchodilator 
measures of lung function utilized in this study are highly 
correlated. Only the association of the IL6 rs2069825 SNP 
with mean number of cigarettes smoked per day on rate 
of decline of prebronchodilator FEV1 was significant after 
correction for multiple comparisons. Thus, given the lack of 
formal significance for the other reported results, they should 
be regarded as hypothesis-generating.
In summary, we have demonstrated significant 
interactions of the IL6 rs2069825 and IFNG rs2069727 
SNPs with cigarette smoking on lung function in a well-
powered cohort of exsmokers and current smokers. In 
addition, the IL6 rs2069825 SNP was also associated 
with cardiovascular   disease. Because several large 
randomized clinical trials and population-based studies 
have demonstrated a substantial reduction in the risk of 
cardiovascular disease and loss of lung function follow-
ing smoking cessation.60–62 We propose that individuals 
with the IL6 rs2069825 SNP would be at risk for the 
development of both COPD and cardiovascular disease, 
and could be targeted in future therapeutic strategies 
aimed at the IL6 pathway.
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